Key clinical point: Patients with COPD maintained respiratory improvements over 52 weeks on revefenacin, a recently approved once-daily bronchodilator.
Major finding: From 3 months until end of trial, all measured health status outcomes in all treatment arms improved at statistically significant levels (P < 0.05).
Study details: Randomized, parallel-group, 52-week trial of 1,055 patients with moderate to very severe COPD
Disclosures: The study was funded by Theravance Biopharma and Mylan.
Donohue JF et al. Resp Res. 2019; 20:241.